Evidence map›Paper›PMID 33120862›Full record

ArticleMetabolites2020

One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL).

Olga V Demler, Yanyan Liu, Heike Luttmann-Gibson, Jeramie D Watrous, Kim A Lagerborg, Hesam Dashti, Franco Giulianini, Mallory Heath, Carlos A Camargo, William S Harris and 15 more

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Supercritical COPlants (Basel, Switzerland) · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 1 country.

Olga V DemlerDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Yanyan LiuDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Heike Luttmann-GibsonDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Jeramie D WatrousDepartment of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.
Kim A LagerborgDepartment of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0003-2490-2191
Hesam DashtiDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Franco GiulianiniDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Mallory HeathDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Carlos A CamargoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.ORCID 0000-0002-5071-7654
William S HarrisOmegaQuant Analytics, Sioux Falls, SD 57106, USA.ORCID 0000-0003-3042-9353
Jay G WohlgemuthQuest Diagnostics, San Juan Capistrano, CA 92673, USA.
Allen M AndresDepartment of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.
Saumya TivariDepartment of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0001-5148-6539
Tao LongDepartment of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.
Mahan NajhawanDepartment of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0003-4027-1203
Khoi DaoDepartment of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.
James G PrenticeQuest Diagnostics, San Juan Capistrano, CA 92673, USA.
Julia A LarsenQuest Diagnostics, San Juan Capistrano, CA 92673, USA.
Olivia I OkerekeDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Karen H CostenbaderDivision of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Julie E BuringDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
JoAnn E MansonDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Susan ChengSmidt Heart Institute, Cedars-Sinai Medical Ctr, Los Angeles, CA 90048, USA.
Mohit JainDepartment of Pharmacology, University of California San Diego, La Jolla, CA 92037, USA.
Samia MoraDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-6283-0980
Brigham and Women's Hospital · USUniversity of California San Diego · USQuest Diagnostics (United States) · USHarvard University · USCedars-Sinai Smidt Heart Institute · US

Funding

Women's Health Study: Continued Follow-upR01CA047988 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 1991 to 2014
$28.2M
VITamin D and omegA-3 triaL (VITAL)U01CA138962 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., MANSON, JOANN ELISABETH · 2009 to 2014
$23.6M
The VITamin D and OmegA-3 TriaL (VITAL)R01CA138962 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., MANSON, JOANN ELISABETH · 2015 to 2019
$20.9M
The Microvascular Aging and Eicosanoids - Women's Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (SCORE)U54AG065141 · NIA · CEDARS-SINAI MEDICAL CENTER · PI BAIREY MERZ, CATHLEEN NOEL, CHENG, SUSAN · 2020 to 2024
$8.7M
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaLR01MH091448 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI OKEREKE, OLIVIA IFEOMA · 2010 to 2019
$6.5M
Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Joint PainR01AR059086 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2010 to 2021
$5.4M
Women's Health Study: Continued Follow-UpR01HL080467 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2005 to 2010
$4.5M
The Women's Health Study: Infrastructure Support for Continued Cohort Follow-upUM1CA182913 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 2014 to 2018
$4.0M
Mapping the Plasma Exposome and its Association with Human Cardiovascular DiseaseR01ES027595 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAIN, MOHIT · 2017 to 2021
$3.3M
Mediators of Systemic Inflammation and Heart Failure Risk in the CommunityR01HL143227 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2019 to 2022
$3.3M
Reducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid PathwaysR01HL134811 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MORA, SAMIA · 2017 to 2020
$3.0M
Cardiovascular Disease Epidemiology in Patients with LupusK24AR066109 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI COSTENBADER, KAREN H · 2014 to 2023
$1.7M
NCI NIH HHS CA-047988NCI NIH HHS CA138962NCI NIH HHS R01 CA138962NCI NIH HHS UM1CA182913NHLBI NIH HHS 1R01HL143227NHLBI NIH HHS 5K01HL135342NHLBI NIH HHS HL-043851NHLBI NIH HHS HL-080467NHLBI NIH HHS HL-099355NHLBI NIH HHS K01 HL135342NHLBI NIH HHS K24 HL136852NHLBI NIH HHS R01HL13416NHLBI NIH HHS R01 HL134811NHLBI NIH HHS R01HL134811NHLBI NIH HHS R01HL143227NIAMS NIH HHS K24 AR066109NIAMS NIH HHS R01 AR059086NIAMS NIH HHS R01AR059086NIA NIH HHS U54AG065141NIDDK NIH HHS K01DK116917NIEHS NIH HHS R01ES027595NIH HHS S10OD020025NIMH NIH HHS R01 MH091448NIMH NIH HHS R01MH091448
6 · The paper itself

Abstract

Omega-3 (n-3) treatment may lower cardiovascular risk, yet its effects on the circulating lipidome and relation to cardiovascular risk biomarkers are unclear. We hypothesized that n-3 treatment is associated with favorable changes in downstream fatty acids (FAs), oxylipins, bioactive lipids, clinical lipid and inflammatory biomarkers. We examined these VITAL200, a nested substudy of 200 subjects balanced on demographics and treatment and randomly selected from the Vitamin D and Omega-3 Trial (VITAL). VITAL is a randomized double-blind trial of 840 mg/d eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) vs. placebo among 25,871 individuals. Small polar bioactive lipid features, oxylipins and FAs from plasma and red blood cells were measured using three independent assaying techniques at baseline and one year. The Women's Health Study (WHS) was used for replication with dietary n-3 intake. Randomized n-3 treatment led to changes in 143 FAs, oxylipins and bioactive lipids (False Discovery Rate (FDR) < 0.05 in VITAL200, validated (

Indexed as

bioactive lipidsclinical trialfree fatty acidsinflammatory biomarkerslipidsmetabolomicsomega-3oxylipins

Identifiers

PMID33120862
PMCPMC7693376
OpenAlexW3097311906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.